CHAMPIONS ONCOLOGY, INC. Remaining Share Repurchase Authorization
CHAMPIONS ONCOLOGY, INC. (CSBR) had Remaining Share Repurchase Authorization of $4.30 million as of 2026-07-31, per its 10-Q filed 2026-09-11.
Financial Statements › Notes › Equity
us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 · last filed 2026-09-11
- 2026-07-31: Stock Repurchase Program, Remaining Authorized Repurchase Amount $4.30M.
- 2026-04-30: Stock Repurchase Program, Remaining Authorized Repurchase Amount $4.30M.
- 2026-01-31: Stock Repurchase Program, Remaining Authorized Repurchase Amount $4.30M.
- 2025-10-31: Stock Repurchase Program, Remaining Authorized Repurchase Amount $4.30M.
| Period end | Stock Repurchase Program, Remaining Authorized Repurchase Amount |
|---|---|
| 2026-07-31 | $4.30M 10-Q · filed 2026-09-11 |
| 2026-04-30 | $4.30M 10-K · filed 2026-07-27 |
| 2026-01-31 | $4.30M 10-Q · filed 2026-03-12 |
| 2025-10-31 | $4.30M 10-Q · filed 2025-12-15 |
| 2025-07-31 | $4.30M 10-Q · filed 2025-09-15 |
| 2025-04-30 | $4.30M 10-K · filed 2025-07-23 |
| 2025-01-31 | $4.30M 10-Q · filed 2025-03-17 |
| 2024-10-31 | $4.30M 10-Q · filed 2024-12-16 |
| 2024-07-31 | $4.30M 10-Q · filed 2024-09-13 |
| 2024-04-30 | $4.30M 10-K · filed 2024-07-19 |
| 2024-01-31 | $4.30M 10-Q · filed 2024-03-15 |
| 2023-10-31 | $4.30M 10-Q · filed 2023-12-13 |
| 2023-07-31 | $4.30M 10-Q · filed 2023-09-13 |
| 2023-04-30 | $4.90M 10-K · filed 2023-07-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |